EP3274714B1 - Manufacturing of a biosensor cartridge - Google Patents

Manufacturing of a biosensor cartridge Download PDF

Info

Publication number
EP3274714B1
EP3274714B1 EP16713837.9A EP16713837A EP3274714B1 EP 3274714 B1 EP3274714 B1 EP 3274714B1 EP 16713837 A EP16713837 A EP 16713837A EP 3274714 B1 EP3274714 B1 EP 3274714B1
Authority
EP
European Patent Office
Prior art keywords
magnetic particles
processing device
magnetic
matrix material
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP16713837.9A
Other languages
German (de)
French (fr)
Other versions
EP3274714A1 (en
Inventor
Ron Martinus Laurentius Van Lieshout
Emiel Peeters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips NV filed Critical Koninklijke Philips NV
Publication of EP3274714A1 publication Critical patent/EP3274714A1/en
Application granted granted Critical
Publication of EP3274714B1 publication Critical patent/EP3274714B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326Magnetic particles
    • G01N33/5434Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing

Definitions

  • the invention relates to a processing device comprising magnetic particles, particularly to a biosensor cartridge. Moreover, it relates to a method for manufacturing such a device.
  • WO 2006/134546 A2 discloses magnetic biosensors with a sensing surface that is coated with binding sites which can specifically bind to target components either carried by magnetic beads or labeled by magnetic beads. Documents further disclose various procedures to dynamically distinguish between magnetic beads which are specifically or un-specifically bound to the binding sites, respectively.
  • the invention relates to a method for manufacturing a processing device that comprises magnetic particles.
  • the method comprises the following steps:
  • Microx material may be for example a sugar compound (e.g. sucrose, trehalose, dextrans, sorbitol, etc. and combination thereof), or an amorphous vitrified material in a broader sense with a glass transition temperature above room temperature, or a polymer
  • a "volatile material” is more volatile than water.
  • an organic solvent can be used if the matrix material is a polymer.
  • the “deposition surface” may be made of any type of material, for instance COP ("cyclo-olefin copolymer”), polystyrene, PMMA, glass, cellulose.
  • COP cyclo-olefin copolymer
  • polystyrene polystyrene
  • PMMA polystyrene
  • glass glass
  • cellulose cellulose
  • the pulling step b) may (at least temporarily) be executed in parallel to the depositing step a), in parallel to the drying step c), or in parallel to both the depositing step a) and the drying step c). Most preferably, it is executed in parallel to the drying step c).
  • the processing device may in general serve any purpose, particularly the processing of a sample or substance using the magnetic particles comprised by the device.
  • a typical example of such a processing is the detection of target molecules in a biological sample with the help of magnetic particles that specifically bind to said molecules.
  • magnetic particles shall comprise both permanently magnetic particles as well as magnetizable particles, for example superparamagnetic beads.
  • the size of the magnetic particles typically ranges between 3 nm and 50 ⁇ m, in particular between 100 nm to 2 ⁇ m, or in particular around 500 nm.
  • the magnetic particles may comprise binding molecules for target components one is actually interested in.
  • drying shall imply that, after removal of the volatile carrier, the initially liquid mixture solidifies, leaving behind matrix material and magnetic particles.
  • the mixture comprises magnetic particles and other components which after evaporation of the volatile carrier (e.g. water) create a matrix which fixates the magnetic particles and keeps the biological components stable.
  • the pulling of the magnetic particles to a desired location within the mixture may be done by an appropriate magnetic field, which usually requires that said magnetic field has a non-zero gradient at the location of the magnetic particles. Additionally or alternatively, the pulling may be achieved by the effect of gravity and/or by inertial or centrifugal forces.
  • matrix material and magnetic particles are separated from each other according to their density, with the material of higher density taking a position below the material of lower density with respect to the direction of the effective force.
  • drying may for example be done in an upside down arrangement of (from top to bottom with respect to gravity) the deposition surface, the matrix material, and the magnetic beads.
  • the magnetic particles may be pulled to any location within the mixture that is desired due to given design or processing criteria.
  • the magnetic particles of the mixture may be pulled away from the deposition surface.
  • preventing a contact of the magnetic particles to the deposition surface has several advantages, which will be discussed in more detail below with respect to particular embodiments of the invention.
  • the term "Away" means that the magnetic particles are sufficiently far from the surface for not having specific and non-specific binding (or interaction) with it (chemically and/or physically). It is in particular preferable that the beads do not touch the surface during the process.
  • the magnetic field that may be generated during the pulling step b) has a non-zero gradient that is substantially perpendicular to the deposition surface.
  • the magnetic particles will then tend to form chains that extend substantially parallel to the deposition surface.
  • the deposition surface may be any kind of surface of a solid body that is suited for the intended application of the processing device, for example a surface on a cover (or laminate) of a cartridge.
  • the surface onto which the mixture is deposited may be a surface called "reaction surface" because physical and/or chemical reactions take place at it during usage of the processing device.
  • said reaction surface may at least locally be coated with binding sites that can specifically bind target substances.
  • the reaction surface may for instance comprise one or more spots coated with such binding sites.
  • the binding sites may particularly be molecules that can specifically bind to target components in a sample, for example antibodies that bind to associated antigens.
  • the aforementioned binding sites can be used in combination with magnetic particles for the detection of a target substance in a sample.
  • the magnetic particles may for example have surface molecules that compete with the target substance for the binding sites. The higher the concentration of the target substances in a given sample, the less magnetic particles will have a chance to bind to the reaction surface. A quantitative determination of the magnetic particles bound to the reaction surface will hence allow for the determination of the concentration of target substances.
  • Another example is a sandwich assay in which a target substance is needed to link a binding site to a magnetic particle.
  • the deposition surface is treated, before the depositing step a), with a blocking substance that (preferably reversibly) binds to "binding points".
  • binding point is used as a generic expression for any entity on the deposition surface to which components of an assay can permanently or temporarily bind, including (specific and unspecific) binding sites for magnetic beads with or without analyte.
  • the treatment with blocking substance prevents that magnetic particles form undesired (specific or unspecific) bindings to said binding points on the deposition surface while they are still free to move within the liquid mixture that is applied in step a).
  • the level of detection of an assay can be increased due to a reduction of the blank (i.e. assay response when no analyte of interest is available).
  • the blocking substance may at least partially stay on the binding points to prevent (un)specific binding during the execution of the actual assay that shall be performed with a processing device.
  • the volatile carrier may be any substance suited for the application at hand that is compatible with the matrix material and the magnetic particles.
  • the volatile carrier may be or comprise an aqueous liquid such as water.
  • the drying step c) can simply comprise the naturally occurring evaporation of water from the mixture, possibly assisted or accelerated by an increase of temperature and/or forced ventilation.
  • the invention relates to a processing device, particularly to a biosensor cartridge, which comprises the following components:
  • the processing device may particularly be manufactured by the method described above. Explanations provided for the method and its variations are therefore analogously valid for the processing device, too, and vice versa.
  • the processing device has the advantage that the non-uniform distribution of magnetic particles can be used to favorably affect the processing steps executed in the device.
  • the magnetic particles form chains that are oriented substantially parallel to the deposition surface.
  • this condition shall particularly be fulfilled after completion of the drying step c), but it may be fulfilled during the other steps, too.
  • the magnetic particles are disposed a distance away from the deposition surface.
  • matrix material is arranged between the deposition surface and the magnetic particles, which has the advantage to prevent undesired bindings of magnetic particles to the surface.
  • the term "Away" means that the magnetic particles are sufficiently far from the surface for not interacting with it (chemically and/or physically).
  • the sub-region comprising the magnetic beads may particularly be a top layer of the matrix material, or any other region not in contact with the surface such that the magnetic particles are not interacting with it.
  • the matrix material comprises at least one material selected from group consisting of sucrose, salt, buffer components, blocking components and assay reagents.
  • the matrix material may optionally be water soluble.
  • the processing device may comprise an optical component that allows for the optical detection of magnetic particles bound to a reaction surface of the device.
  • Said optical component may for example comprise a transparent body on which the reaction surface is formed, wherein said body is appropriately shaped to guide light from a light source to the reaction surface and/or to guide light originating at the reaction surface (e.g. from a reflection) to an (e.g. external) light sensor.
  • the processing device may particularly be designed as a cartridge allowing for an optical detection via Frustrated Total Internal Reflection (FTIR) as it is described in detail for example in the WO 2008/155716 A1 or the WO 2008/115723 A1 , or the "double refraction detection" with e.g. a wedge-like optical structure at the binding spot (cf. e.g. WO 2009/125339 A2 ).
  • FTIR Frustrated Total Internal Reflection
  • Other examples comprise the optical detection of single beads (cf. e.g. WO 2011/036634A1 ,).
  • the magnetic particles may be disposed upstream of a target location, wherein the term "upstream" is to be understood with respect to the intended flow of a fluid in the processing device.
  • the "target location” may be any position inside the processing device where the presence of magnetic particles is desired during an assay to be executed with the device.
  • the magnetic particles are preferably disposed at such a location that they will be transported, by a fluid filling the processing device, just to the target location.
  • the target location may for example be a spot of binding sites that can specifically bind target substances of a sample.
  • the specific detection of marker molecules in bodily fluids may for example be achieved in biosensor platforms such as the Magnotech® technology or a Single Bead Detection developed by the applicant.
  • An example of a marker molecule is troponin-I (cTnI) for the detection of cardio-vascular disease.
  • the detection technique is based on immuno-assays in combination with the optical detection of "magnetic particles” (e.g. superparamagnetic nanoparticles or beads) on a "reaction surface” of a cartridge.
  • the mentioned platforms use Total Internal Reflection (TIR) illumination by creating an evanescent optical field near the surface.
  • TIR Total Internal Reflection
  • the cartridge may consist of a base-part (consisting of fluidic structure, reaction chambers, reactive spots and optical detection), laminate (for closing the cartridge and placing the magnetic beads in the reaction chamber), and a blood housing (for filtering the cell fraction from the plasma fraction in a blood sample).
  • the magnetic beads are disposed on top of the laminate, which is placed on top of the cartridge in such a way that the beads are inside the reaction chamber.
  • the beads can alternatively be placed on top of a reactive spot that is present on the base-part in the reaction chamber.
  • an embodiment of the present invention proposes pulling magnetic beads away from the reaction surface, for example by applying a magnetic field on a droplet comprising magnetic beads during drying or by sedimentation (i.e. gravity). This will position the magnetic beads to the top of the droplet preventing interaction with the reaction surface. A glassy state of the dried bead droplet may prevent the magnetic beads from interacting with the reaction surface after the magnetic field has been removed.
  • the configuration of the magnet usually creates chains of magnetic beads substantially parallel to the reaction surface which are pulled upward away from the surface (see Fig. 5 in comparison with Fig. 6 ). Said chains can be detected after drying, e.g. in bright field microscope images, and allow for a distinction of the resulting dried body from a body obtained by ordinary procedures.
  • Figure 1 schematically illustrates a section through the base-part 111 of a cartridge 110 according to an embodiment of the aforementioned concepts.
  • the base-part 111 has a reaction surface 113 that extends in x,y-direction and carries a detection spot with binding sites 112 for target molecules (usually the reaction surface features a plurality of such detection spots with binding sites for the same or for different target molecules).
  • a droplet D of a mixture comprising magnetic particles MP, a "matrix material", and a volatile carrier (e.g. water) has been deposited on the binding sites 112.
  • the Figure further illustrates a magnetic field generator, here a permanent magnet 120, that is arranged (in z-direction) above the droplet D with its axis extending in x-direction parallel to the reaction surface 113.
  • the distance of the magnet 120 from the reaction surface 113 is adjusted such that a magnetic field B is generated within the droplet D that is substantially parallel to the reaction surface and that has a field gradient substantially perpendicular to said surface (i.e. pointing in z-direction). Due to said field gradient, the magnetic particles MP are attracted towards the magnet 120, i.e. pulled away from the reaction surface 113, and collect at the top surface of the droplet D.
  • a contact between the magnetic particles MP and the binding sites 112 - and hence an undesired binding of the magnetic particles MP to the binding sites 112 - is prevented.
  • the distance between the magnet 120 and the magnetic beads MP is smaller than about 10 mm to properly pull the magnetic beads to one side of the droplet.
  • the distance should however not be too small (e.g. ⁇ 1 mm) in order to prevent magnetic bead migration outside the droplet.
  • a magnetic field perpendicular to the reaction surface could also be used.
  • the resulting chains of magnetic particles will then usually occupy a larger depth within the droplet perpendicular to the reaction surface (i.e. in z-direction).
  • the magnetic bead chains When applying a magnetic field that is parallel to the reaction surface (as shown in Figure 1 ), the magnetic bead chains will occupy a smaller depth, which is preferred in a droplet with limited thickness perpendicular to the reaction surface (the diameter of the droplet D typically ranges between about 50 ⁇ m and about 100 ⁇ m).
  • the volatile carrier of the droplet D will eventually evaporate.
  • This process can optionally be supported by a (moderate) increase of temperature of the droplet D and/or a ventilation of dry air along the droplet D.
  • an additional blocking step may be applied to further decrease the chance that a magnetic bead will bind non-specifically to the reaction surface.
  • the blocking step may particularly comprise the addition of an inert protein (e.gBSA, Caseine) which (reversibly) binds to (unspecific) binding points both inside and outside the binding spots. Because the area inside the binding spots may contain proteins (e.g. antibodies as the binding sites 112), this is essentially already blocked.
  • an inert protein e.gBSA, Caseine
  • Figure 2 illustrates the situation after a complete removal of the volatile carrier.
  • a solid mass has formed that comprises a body of the matrix material MX immediately above the reaction sites 112 and a layer of magnetic particles MP within a top part of said matrix material.
  • the spatial separation between magnetic particles MP and the binding sites 112 has been permanently fixed.
  • the typically glassy body of the matrix material MX prevents degradation of the binding sites (e.g. proteins, antibodies).
  • a laminate or cover 114 is finally attached to the base-part 111 in order to close the reaction chamber(s), channels etc. of the cartridge 110 (these details are not shown in the Figures).
  • the laminate or cover 114 is applied onto the base-part 111 before the drying and before or during or after the application of said magnetic field.
  • the cover 114 may be further arranged to keep or attach the magnetic particles MP onto its surface, optionally through the application of an appropriate magnetic field attracting the magnetic particles MP towards the surface of the cover 114 (and away from the surface of the base-part 111).
  • the magnetic particles may be applied in the liquid mixture or droplet D on the surface of the cover 114 (instead of on the base-part 111). Thereafter, one may assembly the cover 114 with the base-part 111, apply a magnetic field, during or just after this assembly, to pull the magnetic particles MP of the mixture D to a desired location of the mixture D (e.g. towards the surface of the cover 114), and finally dry.
  • the droplet D can be inserted between the cover 114 and the base-part 111 already assembled one to the other, and the invention is implemented thereafter.
  • a liquid sample (not shown) will be filled in the reaction chamber, dissolving the magnetic particles MP and the matrix material MX above the binding sites 112. The detection of target components in the sample (or whatever assay is intended) can then proceed.
  • the problem may arise that if the filling of the cartridge is slow the magnetic beads MP are pulled to the outlet of the reaction chamber, i.e. away from the binding sites 112.
  • these components may therefore optionally be disposed at a location "upstream" of the binding sites 112 to compensate for the displacement during filling.
  • the positioning of the droplet may substantially be left as it is, but the distribution of the magnetic beads in the droplet is changed such that the beads concentrate in a sub-region located "upstream".
  • a droplet of matrix material, volatile carrier, and magnetic beads may hence also be deposited on the cover 114 and dried while a magnetic field pulls the magnetic particles to an "upstream" position within the droplet.
  • magnetic beads MP have been dosed in a quantity of about 50 nl on the base-part 111 on top of an antibody spot 112.
  • the magnetic beads were comprised in a solution containing buffering components, salts and sucrose, among other things. After dosing the magnetic beads were dried for about 30 min at about 37°C. During this drying process an external magnetic field was applied on a distance of about 5 mm with a magnet that creates a field that is parallel to the reaction surface. After the drying phase the magnetic field was removed and the cartridge was processed using the normal procedure.
  • the reduction of non-specific binding was measured for different preparation procedures using a single bead detection technology.
  • This technology provides a surface specific image showing the amount of magnetic beads bound to the surface. The amount of magnetic beads can directly be translated to a FTIR signal change.
  • Figure 3 shows four images of reaction surfaces obtained by single magnetic bead imaging during a washing phase of a blank sample (plasma pool containing no target analyte). Each dark spot in the images corresponds to a magnetic bead bound to the reaction surface.
  • the preparation conditions for the four images were as follows:
  • Figure 4 shows in a diagram the results of a magnetic bead count for the four different configurations A, B, C, and D shown in Figure 3 (the vertical axis indicating the counted number of beads).
  • the hatched bars "in_Sp” correspond to a magnetic bead count (corrected for area) inside the region of interest (ROI) of the printed antibody spots.
  • the white bars "out Sp” correspond to the area outside the printed spots.
  • the magnetic bead count is for the configuration of test "D" on par with the bead count seen when the magnetic beads are dosed on the laminate and thus when there is no interaction of the magnetic beads with the surface during processing.
  • the described approach has an advantage when measurements in a "dirty matrix" (i.e. blood) are made. This is because placing the magnetic beads on top of the reaction/binding surface reduces variation and increases assay performance. This is due to the fact that the blood-cells make the transportation of the beads from the laminate to the reaction/binding surface difficult.
  • a "dirty matrix” i.e. blood
  • embodiments of the invention have been described in which a mixture of magnetic particles, a matrix material, and a volatile carrier is deposited onto binding sites of a reaction surface. The deposited mixture is then dried while the magnetic particles are pulled away from the reaction surface by a magnetic field. Thus unspecific binding of magnetic particles to the binding sites can be prevented.

Description

    FIELD OF THE INVENTION
  • The invention relates to a processing device comprising magnetic particles, particularly to a biosensor cartridge. Moreover, it relates to a method for manufacturing such a device.
  • BACKGROUND OF THE INVENTION
  • The WO 2006/134546 A2 , WO2006/079998 and Bruls et al. ("Rapid integrated biosensor for multiplexed immunoassays based on actuated magnetic nanoparticles", Lab Chip, 2009, 9, 3504-3510 - Oct 13, 2009) disclose magnetic biosensors with a sensing surface that is coated with binding sites which can specifically bind to target components either carried by magnetic beads or labeled by magnetic beads. Documents further disclose various procedures to dynamically distinguish between magnetic beads which are specifically or un-specifically bound to the binding sites, respectively.
  • SUMMARY OF THE INVENTION
  • It would be advantageous to provide means that allow for a detection of analyte of interest with higher accuracy.
  • This object is addressed by a processing device according to claim 1 and a method according to claim 2. Preferred embodiments are disclosed in the dependent claims.
  • According to a first aspect, the invention relates to a method for manufacturing a processing device that comprises magnetic particles. The method comprises the following steps:
    1. a) Depositing a quantity of a liquid mixture comprising magnetic particles, a first material, and a second material onto a surface ("deposition surface") of the processing device. The first material will in the following be called "matrix material" because it serves as a kind of matrix after accomplishment of the device, and the second material will be called "volatile carrier" because it mainly serves as a carrier for the magnetic particles and the matrix material that later on evaporates.
  • "Matrix material" may be for example a sugar compound (e.g. sucrose, trehalose, dextrans, sorbitol, etc. and combination thereof), or an amorphous vitrified material in a broader sense with a glass transition temperature above room temperature, or a polymer
  • As it is known in the literature, a "volatile material" is more volatile than water. For example, an organic solvent can be used if the matrix material is a polymer.
  • Therefore, after the volatile material has been removed, a "glassy substrate" (matrix) typically remains.
  • The "deposition surface" may be made of any type of material, for instance COP ("cyclo-olefin copolymer"), polystyrene, PMMA, glass, cellulose.
    • b) Pulling the aforementioned magnetic particles of the mixture to a desired location within the mixture.
    • c) Drying the mixture by removing the volatile carrier.
  • The steps of the method may be executed in the listed or any other appropriate order. In particular, the pulling step b) may (at least temporarily) be executed in parallel to the depositing step a), in parallel to the drying step c), or in parallel to both the depositing step a) and the drying step c). Most preferably, it is executed in parallel to the drying step c).
  • The processing device may in general serve any purpose, particularly the processing of a sample or substance using the magnetic particles comprised by the device. A typical example of such a processing is the detection of target molecules in a biological sample with the help of magnetic particles that specifically bind to said molecules.
  • The term "magnetic particles" shall comprise both permanently magnetic particles as well as magnetizable particles, for example superparamagnetic beads. The size of the magnetic particles typically ranges between 3 nm and 50 µm, in particular between 100 nm to 2 µm, or in particular around 500 nm. Moreover, the magnetic particles may comprise binding molecules for target components one is actually interested in.
  • The term "drying" shall imply that, after removal of the volatile carrier, the initially liquid mixture solidifies, leaving behind matrix material and magnetic particles. In a typical application, the mixture comprises magnetic particles and other components which after evaporation of the volatile carrier (e.g. water) create a matrix which fixates the magnetic particles and keeps the biological components stable.
  • The pulling of the magnetic particles to a desired location within the mixture may be done by an appropriate magnetic field, which usually requires that said magnetic field has a non-zero gradient at the location of the magnetic particles. Additionally or alternatively, the pulling may be achieved by the effect of gravity and/or by inertial or centrifugal forces. In this case matrix material and magnetic particles are separated from each other according to their density, with the material of higher density taking a position below the material of lower density with respect to the direction of the effective force. In the typical case that the magnetic particles have a higher density than the matrix material, drying may for example be done in an upside down arrangement of (from top to bottom with respect to gravity) the deposition surface, the matrix material, and the magnetic beads.
  • The magnetic particles may be pulled to any location within the mixture that is desired due to given design or processing criteria. In particular, the magnetic particles of the mixture may be pulled away from the deposition surface. This yields a processing device comprising magnetic particles which do not immediately contact the deposition surface because the magnetic particles are pulled away from it, e.g. by a magnetic field, wherein this configuration is fixed or "frozen" during the drying step. It turns out that preventing a contact of the magnetic particles to the deposition surface has several advantages, which will be discussed in more detail below with respect to particular embodiments of the invention. In other words, the term "Away" means that the magnetic particles are sufficiently far from the surface for not having specific and non-specific binding (or interaction) with it (chemically and/or physically). It is in particular preferable that the beads do not touch the surface during the process.
  • According to a preferred embodiment of the method, the magnetic field that may be generated during the pulling step b) has a non-zero gradient that is substantially perpendicular to the deposition surface. The magnetic particles will then tend to form chains that extend substantially parallel to the deposition surface.
  • In general, the deposition surface may be any kind of surface of a solid body that is suited for the intended application of the processing device, for example a surface on a cover (or laminate) of a cartridge. In a preferred embodiment, the surface onto which the mixture is deposited may be a surface called "reaction surface" because physical and/or chemical reactions take place at it during usage of the processing device. Moreover, said reaction surface may at least locally be coated with binding sites that can specifically bind target substances. The reaction surface may for instance comprise one or more spots coated with such binding sites. The binding sites may particularly be molecules that can specifically bind to target components in a sample, for example antibodies that bind to associated antigens.
  • There are several possibilities how the aforementioned binding sites can be used in combination with magnetic particles for the detection of a target substance in a sample. In a competition assay, the magnetic particles may for example have surface molecules that compete with the target substance for the binding sites. The higher the concentration of the target substances in a given sample, the less magnetic particles will have a chance to bind to the reaction surface. A quantitative determination of the magnetic particles bound to the reaction surface will hence allow for the determination of the concentration of target substances. Another example is a sandwich assay in which a target substance is needed to link a binding site to a magnetic particle.
  • In another embodiment of the invention, the deposition surface is treated, before the depositing step a), with a blocking substance that (preferably reversibly) binds to "binding points". In this context, the term "binding point" is used as a generic expression for any entity on the deposition surface to which components of an assay can permanently or temporarily bind, including (specific and unspecific) binding sites for magnetic beads with or without analyte. The treatment with blocking substance prevents that magnetic particles form undesired (specific or unspecific) bindings to said binding points on the deposition surface while they are still free to move within the liquid mixture that is applied in step a). By reducing the number of such undesired bindings, the level of detection of an assay can be increased due to a reduction of the blank (i.e. assay response when no analyte of interest is available). The blocking substance may at least partially stay on the binding points to prevent (un)specific binding during the execution of the actual assay that shall be performed with a processing device.
  • The volatile carrier may be any substance suited for the application at hand that is compatible with the matrix material and the magnetic particles. In particular, the volatile carrier may be or comprise an aqueous liquid such as water. The drying step c) can simply comprise the naturally occurring evaporation of water from the mixture, possibly assisted or accelerated by an increase of temperature and/or forced ventilation.
  • According to a second aspect, the invention relates to a processing device, particularly to a biosensor cartridge, which comprises the following components:
    • A surface (i.e. a component or body with a surface, said surface in the following being called "deposition surface").
    • A layer of a solidified matrix material that is disposed on said deposition surface.
    • Magnetic particles that are disposed in a (proper) sub-region of the matrix material (e.g. in the top part of the matrix layer) at a distance away from said surface. The magnetic particles will hence have a non-uniform distribution within the matrix material, having a higher concentration in
      said sub-region and a lower concentration in the (non-empty) remainder of the matrix material. Preferably, the concentration of magnetic particles outside said sub-region is zero.
  • The processing device may particularly be manufactured by the method described above. Explanations provided for the method and its variations are therefore analogously valid for the processing device, too, and vice versa. The processing device has the advantage that the non-uniform distribution of magnetic particles can be used to favorably affect the processing steps executed in the device.
  • According to a preferred embodiment of the processing device of the second aspect or of a processing device manufactured with a method according to the first aspect, the magnetic particles form chains that are oriented substantially parallel to the deposition surface. In the method, this condition shall particularly be fulfilled after completion of the drying step c), but it may be fulfilled during the other steps, too.
  • According to an aspect of the invention, the magnetic particles are disposed a distance away from the deposition surface. Hence matrix material is arranged between the deposition surface and the magnetic particles, which has the advantage to prevent undesired bindings of magnetic particles to the surface. In other words, the term "Away" means that the magnetic particles are sufficiently far from the surface for not interacting with it (chemically and/or physically). In this embodiment, the sub-region comprising the magnetic beads may particularly be a top layer of the matrix material, or any other region not in contact with the surface such that the magnetic particles are not interacting with it.
  • In another embodiment of the method and/or of the processing device, the matrix material comprises at least one material selected from group consisting of sucrose, salt, buffer components, blocking components and assay reagents.
  • Additionally or alternatively, the matrix material may optionally be water soluble.
  • According to another embodiment of the method and/or the processing device(s), the processing device may comprise an optical component that allows for the optical detection of magnetic particles bound to a reaction surface of the device. Said optical component may for example comprise a transparent body on which the reaction surface is formed, wherein said body is appropriately shaped to guide light from a light source to the reaction surface and/or to guide light originating at the reaction surface (e.g. from a reflection) to an (e.g. external) light sensor. In this case the processing device may particularly be designed as a cartridge allowing for an optical detection via Frustrated Total Internal Reflection (FTIR) as it is described in detail for example in the WO 2008/155716 A1 or the WO 2008/115723 A1 , or the "double refraction detection" with e.g. a wedge-like optical structure at the binding spot (cf. e.g. WO 2009/125339 A2 ). Other examples comprise the optical detection of single beads (cf. e.g. WO 2011/036634A1 ,).
  • In a further embodiment of the invention, the magnetic particles may be disposed upstream of a target location, wherein the term "upstream" is to be understood with respect to the intended flow of a fluid in the processing device. The "target location" may be any position inside the processing device where the presence of magnetic particles is desired during an assay to be executed with the device. The magnetic particles are preferably disposed at such a location that they will be transported, by a fluid filling the processing device, just to the target location. The target location may for example be a spot of binding sites that can specifically bind target substances of a sample.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • These and other aspects of the invention will be apparent from and elucidated with reference to the embodiments described hereinafter.
  • In the drawings:
    • Fig. 1 schematically illustrates the deposition of a droplet comprising magnetic particles on a reaction surface and the pulling of said magnetic particles away from the surface by a magnetic field;
    • Fig. 2 schematically illustrates a cartridge obtained after completion of the procedure shown in Figure 1;
    • Fig. 3 shows photos of magnetic beads bound to reaction surfaces in tests using different manufacturing methods;
    • Fig. 4 is a diagram representing the counts (vertical axis) of bound magnetic particles in the tests of Figure 3.
    • Fig. 5 is a picture taken from a bright field microscope, showing the dried spot with chains of magnetic particles after having used the present invention.
    • Fig. 6 is a picture taken from a bright field microscope, showing the dried spot without any chain of magnetic particles without having used the present invention.
  • Like reference numbers refer in the Figures to identical or similar components.
  • DETAILED DESCRIPTION OF EMBODIMENTS
  • The specific detection of marker molecules in bodily fluids may for example be achieved in biosensor platforms such as the Magnotech® technology or a Single Bead Detection developed by the applicant. An example of a marker molecule is troponin-I (cTnI) for the detection of cardio-vascular disease. The detection technique is based on immuno-assays in combination with the optical detection of "magnetic particles" (e.g. superparamagnetic nanoparticles or beads) on a "reaction surface" of a cartridge. The mentioned platforms use Total Internal Reflection (TIR) illumination by creating an evanescent optical field near the surface.
  • In a typical embodiment of the aforementioned technologies, the cartridge may consist of a base-part (consisting of fluidic structure, reaction chambers, reactive spots and optical detection), laminate (for closing the cartridge and placing the magnetic beads in the reaction chamber), and a blood housing (for filtering the cell fraction from the plasma fraction in a blood sample). The magnetic beads are disposed on top of the laminate, which is placed on top of the cartridge in such a way that the beads are inside the reaction chamber. To reduce the cost of the cartridge and to simplify the production process, the beads can alternatively be placed on top of a reactive spot that is present on the base-part in the reaction chamber.
  • In the WO 2009/024922 A1 , a method is described for storing magnetic beads close to a reactive site using a magnetic field to make sure the beads are close to the sensor surface for fast reaction and interaction. In some applications, it is observed however that there is a (typically non-specific) interaction of the magnetic beads with the base-part during the drying process. The non-specifically bound magnetic particles may later reduce the level of detection (LoD) and the dynamic range.
  • In order to address the aforementioned issues, an embodiment of the present invention proposes pulling magnetic beads away from the reaction surface, for example by applying a magnetic field on a droplet comprising magnetic beads during drying or by sedimentation (i.e. gravity). This will position the magnetic beads to the top of the droplet preventing interaction with the reaction surface. A glassy state of the dried bead droplet may prevent the magnetic beads from interacting with the reaction surface after the magnetic field has been removed. Moreover, the configuration of the magnet usually creates chains of magnetic beads substantially parallel to the reaction surface which are pulled upward away from the surface (see Fig. 5 in comparison with Fig. 6). Said chains can be detected after drying, e.g. in bright field microscope images, and allow for a distinction of the resulting dried body from a body obtained by ordinary procedures.
  • Figure 1 schematically illustrates a section through the base-part 111 of a cartridge 110 according to an embodiment of the aforementioned concepts. The base-part 111 has a reaction surface 113 that extends in x,y-direction and carries a detection spot with binding sites 112 for target molecules (usually the reaction surface features a plurality of such detection spots with binding sites for the same or for different target molecules). Moreover, a droplet D of a mixture comprising magnetic particles MP, a "matrix material", and a volatile carrier (e.g. water) has been deposited on the binding sites 112.
  • The Figure further illustrates a magnetic field generator, here a permanent magnet 120, that is arranged (in z-direction) above the droplet D with its axis extending in x-direction parallel to the reaction surface 113. The distance of the magnet 120 from the reaction surface 113 is adjusted such that a magnetic field B is generated within the droplet D that is substantially parallel to the reaction surface and that has a field gradient substantially perpendicular to said surface (i.e. pointing in z-direction). Due to said field gradient, the magnetic particles MP are attracted towards the magnet 120, i.e. pulled away from the reaction surface 113, and collect at the top surface of the droplet D. Thus a contact between the magnetic particles MP and the binding sites 112 - and hence an undesired binding of the magnetic particles MP to the binding sites 112 - is prevented.
  • In typical embodiments of a cartridge, the distance between the magnet 120 and the magnetic beads MP is smaller than about 10 mm to properly pull the magnetic beads to one side of the droplet. The distance should however not be too small (e.g. < 1 mm) in order to prevent magnetic bead migration outside the droplet.
  • A magnetic field perpendicular to the reaction surface (i.e. running in z-direction) could also be used. However, the resulting chains of magnetic particles will then usually occupy a larger depth within the droplet perpendicular to the reaction surface (i.e. in z-direction). When applying a magnetic field that is parallel to the reaction surface (as shown in Figure 1), the magnetic bead chains will occupy a smaller depth, which is preferred in a droplet with limited thickness perpendicular to the reaction surface (the diameter of the droplet D typically ranges between about 50 µm and about 100 µm).
  • When the configuration of Figure 1 is maintained for some time, the volatile carrier of the droplet D will eventually evaporate. This process can optionally be supported by a (moderate) increase of temperature of the droplet D and/or a ventilation of dry air along the droplet D.
  • Optionally, an additional blocking step may be applied to further decrease the chance that a magnetic bead will bind non-specifically to the reaction surface. The blocking step may particularly comprise the addition of an inert protein (e.gBSA, Caseine) which (reversibly) binds to (unspecific) binding points both inside and outside the binding spots. Because the area inside the binding spots may contain proteins (e.g. antibodies as the binding sites 112), this is essentially already blocked.
  • Figure 2 illustrates the situation after a complete removal of the volatile carrier. A solid mass has formed that comprises a body of the matrix material MX immediately above the reaction sites 112 and a layer of magnetic particles MP within a top part of said matrix material. Thus the spatial separation between magnetic particles MP and the binding sites 112 has been permanently fixed. Moreover, the typically glassy body of the matrix material MX prevents degradation of the binding sites (e.g. proteins, antibodies). A laminate or cover 114 is finally attached to the base-part 111 in order to close the reaction chamber(s), channels etc. of the cartridge 110 (these details are not shown in the Figures).
  • In an alternative embodiment, the laminate or cover 114 is applied onto the base-part 111 before the drying and before or during or after the application of said magnetic field. In that case, the cover 114 may be further arranged to keep or attach the magnetic particles MP onto its surface, optionally through the application of an appropriate magnetic field attracting the magnetic particles MP towards the surface of the cover 114 (and away from the surface of the base-part 111). In this embodiment, the magnetic particles may be applied in the liquid mixture or droplet D on the surface of the cover 114 (instead of on the base-part 111). Thereafter, one may assembly the cover 114 with the base-part 111, apply a magnetic field, during or just after this assembly, to pull the magnetic particles MP of the mixture D to a desired location of the mixture D (e.g. towards the surface of the cover 114), and finally dry. In an alternative, the droplet D can be inserted between the cover 114 and the base-part 111 already assembled one to the other, and the invention is implemented thereafter.
  • When the cartridge 110 is used, a liquid sample (not shown) will be filled in the reaction chamber, dissolving the magnetic particles MP and the matrix material MX above the binding sites 112. The detection of target components in the sample (or whatever assay is intended) can then proceed.
  • During usage of the cartridge 110 the problem may arise that if the filling of the cartridge is slow the magnetic beads MP are pulled to the outlet of the reaction chamber, i.e. away from the binding sites 112. Instead of depositing the droplet with the matrix material MX with the magnetic beads MP above the binding sites 112, these components may therefore optionally be disposed at a location "upstream" of the binding sites 112 to compensate for the displacement during filling. Additionally or alternatively, the positioning of the droplet may substantially be left as it is, but the distribution of the magnetic beads in the droplet is changed such that the beads concentrate in a sub-region located "upstream". This can be achieved in a modification of the arrangement of Figure 1 by pulling the beads in the bead droplet by a magnetic field towards the inlet of the reaction chamber (which may e.g. be at the left side of the processing device in Figures 1, 2) during the drying process. During the filling of the cartridge, the beads are then transported towards the outlet again, however they now end up above the binding sites 112.
  • The aforementioned approach can also be used when magnetic beads are applied to the cover 114 (top of the chamber), where the bead re-dispersion is also important. A droplet of matrix material, volatile carrier, and magnetic beads may hence also be deposited on the cover 114 and dried while a magnetic field pulls the magnetic particles to an "upstream" position within the droplet.
  • In a concrete embodiment of the described procedures, magnetic beads MP have been dosed in a quantity of about 50 nl on the base-part 111 on top of an antibody spot 112. The magnetic beads were comprised in a solution containing buffering components, salts and sucrose, among other things. After dosing the magnetic beads were dried for about 30 min at about 37°C. During this drying process an external magnetic field was applied on a distance of about 5 mm with a magnet that creates a field that is parallel to the reaction surface. After the drying phase the magnetic field was removed and the cartridge was processed using the normal procedure.
  • The reduction of non-specific binding was measured for different preparation procedures using a single bead detection technology. This technology provides a surface specific image showing the amount of magnetic beads bound to the surface. The amount of magnetic beads can directly be translated to a FTIR signal change.
  • Figure 3 shows four images of reaction surfaces obtained by single magnetic bead imaging during a washing phase of a blank sample (plasma pool containing no target analyte). Each dark spot in the images corresponds to a magnetic bead bound to the reaction surface. The preparation conditions for the four images were as follows:
    • Image A (top left) shows a reaction surface obtained without any blocking treatment and without application of a magnetic field during drying.
    • Image B (top right) shows a reaction surface obtained without any blocking treatment but with application of a magnetic field during drying.
    • Image C (bottom left) shows a reaction surface obtained with blocking treatment and without application of a magnetic field during drying.
    • Image D (bottom right) shows a reaction surface obtained with blocking treatment and with application of a magnetic field during drying.
  • The images of Figure 3 clearly show that applying a magnetic field during the drying phase reduces the non-specific interaction time of the magnetic beads with the reaction surface. When applying a blocking step next to the magnetic field, the amount of non-specific interaction is further reduced and brought back to a level which is usually only seen when the magnetic beads are dosed on the laminate, so have no interaction with the surface during drying.
  • Figure 4 shows in a diagram the results of a magnetic bead count for the four different configurations A, B, C, and D shown in Figure 3 (the vertical axis indicating the counted number of beads). The hatched bars "in_Sp" correspond to a magnetic bead count (corrected for area) inside the region of interest (ROI) of the printed antibody spots. The white bars "out Sp" correspond to the area outside the printed spots.
  • The magnetic bead count is for the configuration of test "D" on par with the bead count seen when the magnetic beads are dosed on the laminate and thus when there is no interaction of the magnetic beads with the surface during processing.
  • In comparison to a technology in which magnetic beads are provided on a lid of the cartridge, the described approach has an advantage when measurements in a "dirty matrix" (i.e. blood) are made. This is because placing the magnetic beads on top of the reaction/binding surface reduces variation and increases assay performance. This is due to the fact that the blood-cells make the transportation of the beads from the laminate to the reaction/binding surface difficult.
  • In summary, embodiments of the invention have been described in which a mixture of magnetic particles, a matrix material, and a volatile carrier is deposited onto binding sites of a reaction surface. The deposited mixture is then dried while the magnetic particles are pulled away from the reaction surface by a magnetic field. Thus unspecific binding of magnetic particles to the binding sites can be prevented.

Claims (14)

  1. A processing device comprising:
    - a surface (113);
    - a layer of solidified matrix material (MX) disposed on said surface (113);
    - magnetic particles (MP) disposed in a sub-region of the matrix material (MX) at a distance away from said surface (113).
  2. A method for manufacturing a processing device (110) according to claim 1 comprising magnetic particles (MP), said method comprising the following steps:
    a) depositing a liquid mixture (D) comprising magnetic particles (MP), a matrix material (MX), and a volatile carrier onto a surface (113) of the device;
    b) pulling the magnetic particles (MP) of the mixture (D) away from said surface to a desired location within the mixture;
    c) drying the mixture (D) by removing the volatile carrier.
  3. The method according to claim 2,
    characterized in that the magnetic particles (MP) of the mixture (D) are pulled by a magnetic field (B) in step b).
  4. The method according to claim 3,
    characterized in that a non-zero gradient of the magnetic field (B) is oriented substantially perpendicular to said surface (113).
  5. The method according to claim 2,
    characterized in that said surface is a reaction surface (113) which is at least locally coated with binding sites (112) that can specifically bind target substances.
  6. The method according to claim 2,
    characterized in that said surface (113) is treated with a blocking substance that binds to binding points before the depositing step c).
  7. The method according to claim 2,
    characterized in that the volatile carrier comprises an aqueous liquid.
  8. The processing device (110) according to claim 1,
    characterized in that the magnetic particles (MP) form chains that are oriented substantially parallel to said surface (113).
  9. The method according to claim 1 or the processing device (110) according to claim 1,
    characterized in that the magnetic matrix material (MX) comprises at least one material selected from the group consisting of sucrose, salt, buffer components, blocking components and assay reagents.
  10. The method according to claim 2 or the processing device (110) according to claim 1,
    characterized in that the matrix material (MX) is water-soluble.
  11. The processing device (110) according to claim 1,
    characterized in that it comprises an optical component (111) that allows for the optical detection of magnetic particles (MP) bound to a reaction surface (113) of the device (110).
  12. The method according to claim 2 or the processing device (110) according to claim 1,
    characterized in that the magnetic particles (MP) are disposed upstream of a target location with respect to the intended flow of a fluid in the processing device (100).
  13. The method according or the processing device (110) according to claim 12,
    characterized in that the target location comprises binding sites (112) that can specifically bind target substances.
  14. Processing device (110) according to claim 1, wherein the magnetic particles are stored in a dry state and are arranged according to chains of magnetic particles.
EP16713837.9A 2015-03-26 2016-03-25 Manufacturing of a biosensor cartridge Active EP3274714B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15160948 2015-03-26
PCT/EP2016/056733 WO2016151143A1 (en) 2015-03-26 2016-03-25 Manufacturing of a biosensor cartridge

Publications (2)

Publication Number Publication Date
EP3274714A1 EP3274714A1 (en) 2018-01-31
EP3274714B1 true EP3274714B1 (en) 2019-07-03

Family

ID=52780430

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16713837.9A Active EP3274714B1 (en) 2015-03-26 2016-03-25 Manufacturing of a biosensor cartridge

Country Status (5)

Country Link
US (1) US10690663B2 (en)
EP (1) EP3274714B1 (en)
JP (1) JP6594995B2 (en)
CN (1) CN107407675B (en)
WO (1) WO2016151143A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6829950B2 (en) * 2016-05-31 2021-02-17 シスメックス株式会社 Analytical methods, analyzers and analytical systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037880A1 (en) * 2012-09-04 2014-03-13 Koninklijke Philips N.V. A sensor device and a method of sampling

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324684B (en) * 2002-10-25 2010-05-11 Nat Univ Tsing Hua Micro-array system for micro amount reaction
WO2006079998A1 (en) 2005-01-31 2006-08-03 Koninklijke Philips Electronics N.V. Rapid and sensitive biosensing
WO2006134546A2 (en) 2005-06-17 2006-12-21 Koninklijke Philips Electronics N.V. Accurate magnetic biosensor
CN102841195B (en) * 2005-12-21 2016-02-03 梅索斯卡莱科技公司 There is analysis module and the preparation and application thereof of analytical reagent
US8945946B2 (en) * 2006-03-31 2015-02-03 Canon Kabushiki Kaisha Sensor element and detection method of magnetic particles using this element, and detection method of target substance
US8685754B2 (en) 2006-04-18 2014-04-01 Advanced Liquid Logic, Inc. Droplet actuator devices and methods for immunoassays and washing
US7993525B2 (en) * 2006-12-29 2011-08-09 Intel Corporation Device and method for particle complex handling
CN101674821B (en) 2007-03-19 2013-06-26 Atm麦特保利公司 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid
WO2008118831A2 (en) 2007-03-23 2008-10-02 Advanced Liquid Logic, Inc. Droplet actuator loading and target concentration
EP2034324A3 (en) * 2007-07-20 2010-06-16 Koninklijke Philips Electronics N.V. Sensor cartridge
EP2028491A1 (en) * 2007-08-22 2009-02-25 Koninklijke Philips Electronics N.V. Method of directing magnetic or magnetisable objects to prepare bio-sensor device
JP5628784B2 (en) * 2008-03-17 2014-11-19 コーニンクレッカ フィリップス エヌ ヴェ Cartridge for assay with magnetic particles
EP2108938A1 (en) 2008-04-09 2009-10-14 Koninklijke Philips Electronics N.V. A carrier for optical detection in small sample volumes
WO2010086772A1 (en) 2009-01-29 2010-08-05 Koninklijke Philips Electronics N.V. System and method for assay
US9075052B2 (en) 2009-09-28 2015-07-07 Koninklijke Philips N.V. Biosensor system for single particle detection
US8394325B2 (en) 2010-06-14 2013-03-12 Abbott Point Of Care Inc. Magnetic beads for reducing leukocyte interference in immunoassays
JP6154393B2 (en) 2011-11-03 2017-06-28 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Method and sensor device for detecting magnetic particles
WO2014007034A1 (en) 2012-07-06 2014-01-09 株式会社 日立ハイテクノロジーズ Analysis device and analysis method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037880A1 (en) * 2012-09-04 2014-03-13 Koninklijke Philips N.V. A sensor device and a method of sampling

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANG GAO ET AL: "Disaggregation of microparticle clusters by induced magnetic dipole-dipole repulsion near a surface", LAB ON A CHIP, vol. 13, no. 7, 1 January 2013 (2013-01-01), pages 1394, XP055467649, ISSN: 1473-0197, DOI: 10.1039/c3lc41229f *

Also Published As

Publication number Publication date
JP6594995B2 (en) 2019-10-23
CN107407675B (en) 2020-03-17
WO2016151143A1 (en) 2016-09-29
CN107407675A (en) 2017-11-28
EP3274714A1 (en) 2018-01-31
US10690663B2 (en) 2020-06-23
JP2018509628A (en) 2018-04-05
US20180067110A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US20220326232A1 (en) Magnetic immunosensor with trench configuration and method of use
RU2505816C2 (en) Cartridge for analyses with magnetic particles
US9103843B2 (en) Device and methods for detecting analytes in saliva
US9778254B2 (en) Methods and systems for detecting
US20160109439A1 (en) Magnetic immunosensor and method of use
US20100248394A1 (en) Controlled flow assay device and method
US20160216256A1 (en) Oscillating immunoassay method and device
US20120031773A1 (en) Immunoassay method and device with magnetically susceptible bead capture
JP6627747B2 (en) Sensor chip for surface plasmon excitation enhanced fluorescence spectrometry
JP6291491B2 (en) Treatment of fluids containing interference particles
CA2777807A1 (en) An assay method and devices involving the use of magnetic particles
JP2007271609A (en) Biosensor
EP3274714B1 (en) Manufacturing of a biosensor cartridge
JP2007292564A (en) Biosensor chip
JP2007248318A (en) Biosensor array
US9823241B2 (en) Processing of a sample fluid with target components
JP2012502273A (en) Improved wire grid substrate structure and method of manufacturing such a substrate
WO2024043167A1 (en) Target substance measuring method, and target substance measuring system
WO2024034561A1 (en) Solid phase carrier, and target object measurement kit
JP2007236313A (en) Method for screening nucleic acid molecule and method for detecting/determining specific substance
EP2726874A1 (en) Preparation of reaction chambers with dried proteins

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171026

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180423

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190204

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1151619

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190715

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016016282

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190703

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1151619

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191003

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191104

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191003

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191103

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191004

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: KONINKLIJKE PHILIPS N.V.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016016282

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG2D Information on lapse in contracting state deleted

Ref country code: IS

26N No opposition filed

Effective date: 20200603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200325

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200325

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20210329

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190703

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602016016282

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221001